Homologous Recombination News and Research

RSS

Scientists uncover stem cell response to prolonged irradiation

Researchers from several Russian institutes, including MIPT, have found out how prolonged exposure to ionizing radiation affects human stem cells.

24 Aug 2017

Researchers identify DNA repair deficiency in many types of solid tumors

A new investigation of more than 48,000 stored tumor samples finds evidence of a key deficiency in a repair mechanism designed to keep DNA from being mutated and causing cancer.

18 May 2017

Penn researchers use CRISPR/Cas9 gene targeting approach to treat hemophilia B in mice

CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations.

1 Dec 2016

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.

8 Oct 2016

Tumour suppressor gene has greater anti-cancer activity than previously thought

New insight into the function of a gene important in the suppression of cancer is published today. Researchers at the National University of Ireland Galway have shown that the TP53 gene has even greater anti-cancer activity than previously thought.

22 Sep 2016

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors.

5 Sep 2016

Penn researchers uncover strategy to reverse effects of dyskeratosis congenita

Dyskeratosis congenita, or DC, is a rare, inherited disease for which there are limited treatment options and no cure.

18 Aug 2016

Study focuses on critical proteins involved in ovarian cancer biology

In what is believed to be the largest study of its kind, scientists at the Pacific Northwest National Laboratory, Johns Hopkins University and their collaborators from institutions across the nation have examined the collections of proteins in the tumors of 169 ovarian cancer patients to identify critical proteins present in their tumors.

30 Jun 2016

Research describes how gene BRCA1 plays vital role in DNA repair

Scientists at the University of Birmingham are a step closer to understanding the role of the gene BRCA1. Changes in this gene are associated with a high risk of developing breast and ovarian cancer.

30 May 2016

Continuous errors in damaged DNA repair may lead to tumor formation

A group of researchers at Osaka University found that if DNA damage response (DDR) does not work when DNA is damaged by radiation, proteins which should be removed remain instead, and a loss of genetic information can be incited, which, when repaired incorrectly, will lead to the tumor formation.

25 May 2016

SGO acting on ovarian cancer report recommendations

During the Society of Gynecologic Oncology’s 47th Annual Meeting on Women’s Cancer today, SGO convened a panel of ovarian cancer experts to discuss the recently released report by the National Academy of Medicine (NAM),

24 Mar 2016

Genetic testing in women with ovarian cancer helps determine prognosis

A study examining mutations in DNA repair genes in women with advanced ovarian cancer found that the disease remained at bay longer in women with the mutations than without, and that women having cancers with these mutations lived longer.

24 Mar 2016

Clinical review examines benefit of RT in breast cancer patients with BRCA1, BRCA2 mutations

In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a clinical review examined the current status of data regarding BRCA1 and BRCA2 deficiency and radiation therapy sensitivity and a potential strategy to intensify the effects of radiation therapy (RT) by poly(ADP-ribose) polymerase inhibitors (PARPi), the pharmacologic drugs under investigation as monotherapy for the treatment of breast cancer in patients with BRCA1 and BRCA2 mutations.

9 Mar 2016

Scientists discover small molecule that can block growth of BRCA-deficient cancer cells

Cancer cells with mutations in BRCA1 or BRCA2 genes, which serve a vital role in preserving the integrity of the genetic code, are key targets for cancer therapeutics. Yet, few agents can selectively eliminate cells deficient in BRCA, and none can do so without the risk of inducing drug resistance.

6 Nov 2015

Discovery opens door to more targeted, effective treatments for cancer

In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.

24 Sep 2015

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma was awarded the 2015 Advanced Clinical Research Award in Breast Cancer from the American Society of Clinical Oncology to continue her research on triple-negative breast cancer.

25 Aug 2015

Study findings could lead to new ways to tailor therapies for cancer

By studying the yeast used in beer- and bread-making, researchers at the University of Pittsburgh School of Medicine have uncovered the mechanism by which ancient proteins repair DNA damage and how their dysfunction could lead to the development of tumors.

28 Jul 2015

Caris Molecular Intelligence allows comparisons between tumors sharing histological features

Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of data from three studies that demonstrate the utility of Caris Molecular Intelligence®, the company's panomic comprehensive tumor profiling service, in facilitating comparisons between tumors that share histological features.

1 Jun 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.